Efficacy of lisdexamfetamine dimesylate throughout the day in children and adolescents with attention-deficit/hyperactivity disorder: results from a randomized, controlled trial
David Coghill(The University of Melbourne), Liza Squires, Michel Lecendreux(Laboratoire National de Référence), Alessandro Zuddas(University of Cagliari), Regina Dittmann(Forschungszentrum Jülich), Ralph Bloomfield(AstraZeneca (United Kingdom)), Isabel Hernández Otero(Victoria School of Management), Richard Civil(Takeda (United States)), Tobias Banaschewski(Heidelberg University)
Cited by 33
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders
|Cell|2019|1.5k
The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder
|Neuroscience & Biobehavioral Reviews|2021|1.4k
Attention-deficit/hyperactivity disorder
|Nature Reviews Disease Primers|2015|1.3k